Cellectis S.A.'s pipeline updates highlight promising advancements in engineered, allogeneic cell therapies. The financial overview indicates a strong cash position, but ongoing R&D expenses pose a ...

Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a ...

Shares of Cellectis S.A. (NASDAQ: CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ: ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big ...

Cellectis (NASDAQ:CLLS) Stock, Option Chain Option chain shows key data for Cellectis's stock options at various strike prices and expiration dates. Traders use this information to analyze potential ...